Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Se Hoon Lee

Showing results (191-200 of 513) with videos related to

Pageof 52
Sort By:
Nature Communications|September 21, 2019
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number loadHyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2018
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLCYoujin Kim, Boram Lee, Joon Ho Shim, et al.
Nature Communications|February 21, 2020
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicityKwoneel Kim, Hong Sook Kim, Jeong Yeon Kim, et al.
Korean Journal of Radiology|November 18, 2015
Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR ImagingEun Kyoung Lee, Seung Hong Choi, Tae Jin Yun, et al.
Journal of Neuro-Oncology|June 1, 2015
Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomasByung Sup Kim, Sung Kwon Kim, Seung Hong Choi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2019
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencingHong Sook Kim, Hongui Cha, Jinho Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2010
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutationsDong-Wan Kim, Se-Hoon Lee, Jong Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR InhibitorTae Min Kim, Ahnah Song, Dong-Wan Kim, et al.
Journal of Neuro-Oncology|January 30, 2022
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade gliomaYong-Pyo Lee, Hyun Ae Jung, Min-Sang Lee, et al.
Nature Cancer|June 3, 2024
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic featuresTian-Gen Chang, Yingying Cao, Hannah J Sfreddo, et al.
Pageof 52

Showing results (191-200 of 513) with videos related to

Sort By:
Pageof 52
Nature Communications|September 21, 2019
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number loadHyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2018
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLCYoujin Kim, Boram Lee, Joon Ho Shim, et al.
Nature Communications|February 21, 2020
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicityKwoneel Kim, Hong Sook Kim, Jeong Yeon Kim, et al.
Korean Journal of Radiology|November 18, 2015
Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR ImagingEun Kyoung Lee, Seung Hong Choi, Tae Jin Yun, et al.
Journal of Neuro-Oncology|June 1, 2015
Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomasByung Sup Kim, Sung Kwon Kim, Seung Hong Choi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2019
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencingHong Sook Kim, Hongui Cha, Jinho Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2010
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutationsDong-Wan Kim, Se-Hoon Lee, Jong Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR InhibitorTae Min Kim, Ahnah Song, Dong-Wan Kim, et al.
Journal of Neuro-Oncology|January 30, 2022
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade gliomaYong-Pyo Lee, Hyun Ae Jung, Min-Sang Lee, et al.
Nature Cancer|June 3, 2024
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic featuresTian-Gen Chang, Yingying Cao, Hannah J Sfreddo, et al.
Pageof 52